ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / AMLX / earnings
ACAD (50) OGN (70) XENE (37) IRON (54) ⌘ Pro Terminal →

Amylyx Pharmaceuticals Inc. (AMLX) Next Earnings Date & Expected ±10.1% Move

$28.86 +0.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $28.84

Amylyx Pharmaceuticals Inc. (AMLX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • RED ALERT Cap $3.60B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMLX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AMLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $28.86 (+0.63% 1D, market cap $3.60B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AMLX ranks #543 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AMLX compare to ACAD and OGN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMLX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACAD (ACADIA Pharmaceuticals Inc.) holds a D grade (50/100 RQD, P/E 9.1x, ROIC 7.9%, cap $3.58B) and OGN (Organon & Co.) posts a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMLX?
▼

Per AMLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658551), Amylyx Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$144.7M in net income, and -$123.5M in free cash flow against $332.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $28.84 (-0.08%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510039
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (6)Whales (10)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
$43 Bull$26 Base$21 Bear
📬 FREE AMLX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMLX)Realized 20D OHLCV Swing Band: ±10.1%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY AMLX SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (26% of score)

20D Institutional Volume Accumulation (±10.1% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
31
Grade E$27.48-0.5% Next Q
Q2 (-2Q)
34
Grade E$27.33-0.9% Next Q
Q3 (-1Q)
36
Grade E$27.09+6.5% Next Q
Current
39
Grade D-$28.86-7.6% Hist 90D α
Trajectory: E (31) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AMLX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AMLX currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($30.69) and Max Pain ($30.30) forces dealer call-delta covering toward $43.20.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMLX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AMLX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 39%NO 61%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±10.1% Swing Band

±$2.91 Expected Swing
$25.95 (-10.1%)Spot $28.86$31.77 (+10.1%)
MODEL EARNINGS SETUP GAUGE

AMLX Quantitative Pre-Earnings Setup: 39/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (39/100)Model Risk Weight (61/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$0-$144.7M-$123.5M52%
FY 20242024-12-31$87.4M-$301.7M-$167.8M93.2%
FY 20232023-12-31$380.8M$49.3M$11.9M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMLX)

  • ✓Walkthrough of AMLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AMLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +75.33%🛡️ HOLDING TREND SUPPORT
2026-11-02O $28.07H $28.86L $28.07C $28.86VOL 905.5K
RES: $36.71SUP: $27.35SMA50: $30.69SMA200: $20.15
$43.15$34.83$26.50$18.18$9.86RES $36.71SUP $27.35$28.862026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMLX Butterfly Map → + Track AMLX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AMLX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMLX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMLX)

Health Care Rank #543 of 1016 ⚔️ ACAD vs AMLX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMLX vs. ACAD, OGN, XENE, IRON)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Amylyx Pharmaceuticals Inc. (AMLX) ranks #543 by composite RQD confidence (39/100, grade D-) and #192 by equity capitalization ($3.60B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with AMLX at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AMLX ACTIVE
Amylyx Pharmaceuticals Inc.
D- 39/100 — — -35.0% +0.63% $3.60B Benchmark Subject
ACAD
ACADIA Pharmaceuticals Inc.
D 50/100 9.1x 91.7% 7.9% -0.82% $3.58B /acad-vs-amlx →
OGN
Organon & Co.
B- 70/100 19.4x 53.3% 24.9% +0.22% $3.63B /ogn-vs-amlx →
XENE
Xenon Pharmaceuticals Inc.
D- 37/100 — — -35.0% -0.35% $3.64B /xene-vs-amlx →
IRON
Disc Medicine Inc.
D+ 54/100 — — -27.5% -2.41% $3.68B /iron-vs-amlx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001658551

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amylyx Pharmaceuticals Inc. (AMLX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $87.4M , and -100.0% cumulative change since FY2023) , GAAP net income of -$144.7M, operating cash flow of -$123.3M, and free cash flow of -$123.5M (+26.4% YoY). On the balance sheet, AMLX closed FY2025 with $332.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$144.7M -$123.3M -$123.5M $332.6M —
FY2024 (FY) 2024-12-31 $87.4M -$301.7M -$167.6M -$167.8M $193.6M —
FY2023 (FY) 2023-12-31 $380.8M $49.3M $11.9M $11.9M — —

3. AMLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $28.86 (+0.63% 1D, market cap $3.60B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AMLX ranks #543 in composite RQD confidence.

How does AMLX compare to ACAD and OGN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMLX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACAD (ACADIA Pharmaceuticals Inc.) holds a D grade (50/100 RQD, P/E 9.1x, ROIC 7.9%, cap $3.58B) and OGN (Organon & Co.) posts a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMLX?

Per AMLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658551), Amylyx Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$144.7M in net income, and -$123.5M in free cash flow against $332.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMLX trading relative to its 50-day, 200-day, and 52-week technical levels?

AMLX last traded at $28.86 (+0.63% on volume of 989,547 shares), positioning the stock -5.96% below its 50-day simple moving average ($30.69) and +43.23% above its 200-day simple moving average ($20.15). Across its 52-week range of $10.83 to $41.14, AMLX sits at the 59.5% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±10.1% ($25.95 to $31.77).

AMLX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is AMLX's next earnings date?

Based on SEC filing cadence, Amylyx Pharmaceuticals Inc. (AMLX)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is AMLX stock expected to move on earnings?

Volatility modeling currently projects a ±10.1% event move for AMLX, spanning a range between $25.95 and $31.77.

Direct Sub-Reports: AMLX RQD Cockpit AMLX 12M Forecast AMLX Earnings & Move AMLX Dividends & DRIP AMLX Insiders & 13F AMLX Whale Options AMLX Profit Sankey AMLX News & Why
ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

AMLX — Amylyx Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:23:12Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, AMLX scores 39 out of 100 and carries a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars break down as follows:

  • Fundamental Cash Engine: 6 / 20. This is the weakest contributor. The rating cites ROIC of -35% and an FCF yield of -3.43%, indicating that the business is currently consuming capital rather than generating it relative to its market value.
  • Whale 13F Flow: 10 / 20. Institutional accumulation and options positioning are rated at a mid-range level. This is neutral-to-modestly supportive and does not by itself offset the fundamental weakness.
  • Insider Conviction: 3 / 20. The SEC Form 4 and Congressional PTR cluster flow is rated very low, which suggests limited insider-level confidence signals in the data.
  • Macro Regime Fit: 10 / 20. Beta is 1.0 and the rating notes sector sensitivity. The stock's market sensitivity is average, so it neither amplifies nor dampens broad market moves on this measure.
  • Forensic Balance Sheet: 10 / 20. Per the rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. These readings point to moderate balance-sheet strength on the Altman measure but weak operating-quality signals on Piotroski.

For a prospective investor evaluating the stock today, the rating's implication is that the cash-generation and insider-signal pillars are the primary drags, while institutional flow and balance-sheet metrics are only middling. Upside drivers would need to come from a turn in cash generation, which the current ROIC and FCF yield do not yet show. Valuation tradeoffs are difficult to assess directly because P/E and EV/EBITDA are unavailable in the source data, and the company reports negative earnings in the periods provided. The rating is a quantitative screen and is presented here for educational purposes, not as personalized financial advice.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-153.3M$-144.7MN/A$-123.5M$226.7MN/A
FY 2024$87.4M$-314.7M$-301.7MN/A$-167.8M$77.4MN/A
FY 2023$380.8M$38.8M$49.3MN/A$11.9MN/AN/A

Per the SEC financials, operating and net results moved from positive in FY 2023 to substantial losses in both FY 2024 and FY 2025. Margins are reported as 0% for gross, operating, and net in the market data. Per the Roarable RQD rating, ROIC is -35%, and the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9. Reported cash rose from $77.4M to $226.7M between FY 2024 and FY 2025, and debt is marked N/A in the source data.

Recent Catalysts & News Wire Analysis

Per the news feed, the headlines include a Yahoo Finance report on the stock, a TradingView estimates item, a Simply Wall St forecast item, and a Stock Titan notice that a live call will cover third-quarter results on Nov. 5 at 8 a.m. ET. A Benzinga item references a Q2 2026 earnings call transcript. A TradingView item reports a 12-month price target raised to $43, which the headline states implies 59% upside. The news items are labeled as catalysts or market wire by the feed, with the price-target and Yahoo items flagged green.

Risk watch items per the source data: the upcoming third-quarter results call, and the reported losses and negative FCF in the financial trend. Per the Butterfly Supply-Chain Graph, the supply-chain value is NONE, there are no butterfly links, and there are no proprietary signals. Not available in source data for any additional proprietary signal.

Open Questions

  • What are the company's specific revenue sources after FY 2023, given that reported revenue declined to $0.0M in FY 2025?
  • What is the reason for the change in reported debt, which is marked N/A across all periods?
  • What are the drivers of the increase in cash from $77.4M to $226.7M, and do they reflect operating or financing activity?
  • What is the outcome of the third-quarter results call scheduled for Nov. 5?
  • What are the EPS, P/E, and EV/EBITDA values, which are not available in the source data?

AMLX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Amylyx Pharmaceuticals Inc. (AMLX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AMLX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AMLX Bull vs. Bear Conversation Board — What's Your Call at $28.86?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMLX 🐻 67% BEARISH CONVICTION
1. Pick Your Side on AMLX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $25.24 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is AMLX (D- • RQD 39/100) a Buy at $28.68?

Welcome to the AMLX (Amylyx Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $24.09 (-16.0%)
Spot @ $28.68

Pump the brakes on AMLX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AMLX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Amylyx Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $32.70 (+14.0%)
Spot @ $28.68

AMLX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AMLX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $28.68 (52-wk range $10.83 - $41.14), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%